CLINICAL RESEARCH: HEART RHYTHM DISORDER
Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
Jonathan P. Piccini, MD, MHS*,
Vic Hasselblad, PhD,
Eric D. Peterson, MD, MPH,
Jeffrey B. Washam, PharmD,
Robert M. Califf, MD and
David F. Kong, MD
Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina
Manuscript received March 13, 2009;
revised manuscript received April 22, 2009,
accepted April 28, 2009.
* Reprint requests and correspondence: Dr. Jonathan P. Piccini, Duke Clinical Research Institute, Duke University Medical Center #31115, Durham, North Carolina 27710 (Email: jonathan.piccini{at}duke.edu).
Objectives: We sought to compare the efficacy and safety of dronedarone versus amiodarone for the prevention of recurrent atrial fibrillation (AF).
Background: Dronedarone is a noniodinated amiodarone congener developed to maintain sinus rhythm. Few data are available to directly compare the efficacy and safety of dronedarone versus amiodarone.
Methods: We conducted a systematic overview of all randomized controlled trials in which the authors evaluated dronedarone or amiodarone for the prevention of AF. The effect of amiodarone versus dronedarone was summarized by the use of indirect comparison meta-analysis and normal logistic meta-regression models.
Results: We identified 4 placebo-controlled trials of dronedarone, 4 placebo-controlled trials of amiodarone, and 1 trial of dronedarone versus amiodarone. By using random-effects modeling, we found that there was a significant estimated reduction in recurrent AF with amiodarone versus placebo (odds ratio [OR]: 0.12; 95% confidence interval [CI]: 0.08 to 0.19) but not dronedarone versus placebo (OR: 0.79; 95% CI: 0.33 to 1.87). A normal logistic regression model incorporating all trial evidence found amiodarone superior to dronedarone (OR: 0.49; 95% CI: 0.37 to 0.63; p < 0.001) for the prevention of recurrent AF. In contrast, these models also found a trend toward greater all-cause mortality (OR: 1.61; 95% CI: 0.97 to 2.68; p = 0.066) and greater overall adverse events requiring drug discontinuation with amiodarone versus dronedarone (OR: 1.81; 95% CI: 1.33 to 2.46; p < 0.001).
Conclusions: Dronedarone is less effective than amiodarone for the maintenance of sinus rhythm, but has fewer adverse effects. For every 1,000 patients treated with dronedarone instead of amiodarone, we estimate approximately 228 more recurrences of AF in exchange for 9.6 fewer deaths and 62 fewer adverse events requiring discontinuation of drug.
Key Words: dronedarone amiodarone antiarrhythmic drug therapy atrial fibrillation
|
Abbreviations and Acronyms
| | AF = atrial fibrillation | | CI = confidence interval | | OR = odds ratio |
|
Related Articles
-
Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
- Thorsten Lewalter
J. Am. Coll. Cardiol. 2010 55: 1051-1052.
[Full Text]
[PDF]
-
Dronedarone Is Superior to Placebo: The Case for Optimism
- Jonas A. Cooper
J. Am. Coll. Cardiol. 2010 55: 1052.
[Full Text]
[PDF]
-
Reply
- Jonathan P. Piccini and David F. Kong
J. Am. Coll. Cardiol. 2010 55: 1052-1053.
[Full Text]
[PDF]
-
Amiodarone or Dronedarone for Atrial Fibrillation: Too Early to Know the Winner?
- Paul S. Chan, Brahmajee K. Nallamothu, and Hakan Oral
J. Am. Coll. Cardiol. 2009 54: 1096-1098.
[Full Text]
[PDF]
-
Inside This Issue
J. Am. Coll. Cardiol. 2009 54: A22.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
E. K. Heist, M. Mansour, and J. N. Ruskin
Rate Control in Atrial Fibrillation: Targets, Methods, Resynchronization Considerations
Circulation,
December 13, 2011;
124(24):
2746 - 2755.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Hampton
Commentary: The need for clinical freedom
Int. J. Epidemiol.,
August 1, 2011;
40(4):
849 - 852.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Y. H. Lip, J. L. Halperin, and H.-F. Tse
The 2010 European Society of Cardiology Guidelines on the Management of Atrial Fibrillation: An Evolution or Revolution?
Chest,
April 1, 2011;
139(4):
738 - 741.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Freemantle, C. Lafuente-Lafuente, S. Mitchell, L. Eckert, and M. Reynolds
Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation
Europace,
March 1, 2011;
13(3):
329 - 345.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. Piccini and D. F. Kong
Mixed treatment comparisons for atrial fibrillation: evidence network or bewildering entanglement?
Europace,
March 1, 2011;
13(3):
295 - 296.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. S. Wann, A. B. Curtis, C. T. January, K. A. Ellenbogen, J. E. Lowe, N. A. M. Estes III, R. L. Page, M. D. Ezekowitz, D. J. Slotwiner, W. M. Jackman, et al.
2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
J. Am. Coll. Cardiol.,
January 11, 2011;
57(2):
223 - 242.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
2011 Writing Group Members, L. S. Wann, A. B. Curtis, C. T. January, K. A. Ellenbogen, J. E. Lowe, N. A. M. Estes III, R. L. Page, M. D. Ezekowitz, D. J. Slotwiner, et al.
2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Circulation,
January 4, 2011;
123(1):
104 - 123.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Burashnikov, S. Sicouri, J. M. Di Diego, L. Belardinelli, and C. Antzelevitch
Synergistic Effect of the Combination of Ranolazine and Dronedarone to Suppress Atrial Fibrillation
J. Am. Coll. Cardiol.,
October 5, 2010;
56(15):
1216 - 1224.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Developed with the special contribution of the Eur, Endorsed by the European Association for Cardio-Th, Authors/Task Force Members, A. J. Camm, P. Kirchhof, G. Y. H. Lip, U. Schotten, I. Savelieva, S. Ernst, I. C. Van Gelder, et al.
Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
Eur. Heart J.,
October 1, 2010;
31(19):
2369 - 2429.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Developed with the special contribution of the Eur, Endorsed by the European Association for Cardio-Th, Authors/Task Force Members, A. J. Camm, P. Kirchhof, G. Y. H. Lip, U. Schotten, I. Savelieva, S. Ernst, I. C. Van Gelder, et al.
Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
Europace,
October 1, 2010;
12(10):
1360 - 1420.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. Tichy, A. J. Medwid, E. A. Mills, R. N. Formica, and S. Kulkarni
Significant Sirolimus and Dronedarone Interaction in a Kidney Transplant Recipient
Ann. Pharmacother.,
July 1, 2010;
44(7):
1338 - 1341.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Kalus
Pharmacotherapeutic decision-making for patients with atrial fibrillation
Am. J. Health Syst. Pharm.,
May 1, 2010;
67(9_Supplement_5):
S17 - S25.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Lewalter
Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
J. Am. Coll. Cardiol.,
March 9, 2010;
55(10):
1051 - 1052.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Cooper
Dronedarone Is Superior to Placebo: The Case for Optimism
J. Am. Coll. Cardiol.,
March 9, 2010;
55(10):
1052 - 1052.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. Piccini and D. F. Kong
Reply
J. Am. Coll. Cardiol.,
March 9, 2010;
55(10):
1052 - 1053.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, G. K. Feld, B. H. Greenberg, J. Hall, M. Hlatky, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, et al.
Highlights of the Year in JACC 2009
J. Am. Coll. Cardiol.,
January 26, 2010;
55(4):
380 - 407.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Amiodarone or Dronedarone for Atrial Fibrillation?
Journal Watch (General),
October 13, 2009;
2009(1013):
2 - 2.
[Full Text]
|
 |
|

|
 |

|
 |
 
P. S. Chan, B. K. Nallamothu, and H. Oral
Amiodarone or Dronedarone for Atrial Fibrillation: Too Early to Know the Winner?
J. Am. Coll. Cardiol.,
September 15, 2009;
54(12):
1096 - 1098.
[Full Text]
[PDF]
|
 |
|
|